# Zewei Biological

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zewei-biological

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Total disclosed funding: $1.5M
- Latest round: Angel (Apr 11, 2023)
- Investors on record: 3

## About

Based in Nanjing, China, and established in 2022, Zewei Biological is a biotechnology company that focuses on the R&D of target drugs for tumors. The company was established by Doctor Wei He, who graduated from Molecular Cell Development at The Ohio State University, USA, and served as a principal researcher at Novartis US.  In April 2023, it raised CNY 10 million in angel funding from new investors InnoMed Capital, Nanjing Fuze, and Suzhou Yuming Private Equity Fund Management. 

Zewei Biological provides target discovery, target validation, biological mechanism research, and preclinical research for the R&D of new drugs. It self-developed tumor situ target capture technology platform TRiC, which can broaden drug target development scope, and improve the success rate of drug target discovery.

## Funding rounds

- Angel, Apr 11, 2023, $1.5M — InnoMed Capital, Suzhou Yuming Private Equity Fund Management, Nanjing Fuze

## Investors

- InnoMed Capital (https://capitalatlas.ai/funds/innomed-capital) — Angel
- Suzhou Yuming Private Equity Fund Management — Angel
- Nanjing Fuze — Angel